🏢 What kind of company is Axsome Therapeutics?

Axsome Therapeutics (AXSM) is a U.S. biopharmaceutical company that develops therapies for central nervous system (CNS) disorders affecting the brain and nervous system, including depression, sleep disorders, and migraine. The company develops its own drugs and has moved them into commercialization, selling them directly.

Revenue is generated from the direct sale of its in-house CNS therapies. The company sells its own depression and sleep-disorder treatments, and the sales growth of these drugs is the core of its earnings. It is broadening growth drivers by expanding indications for existing drugs and developing a follow-on pipeline of new drugs targeting various CNS conditions such as migraine.

💰 How does Axsome Therapeutics make money?

Business Segment	Revenue Mix	Description
Marketed Drugs	Core	Direct sales of in-house CNS treatments for depression and sleep disorders, representing the largest revenue share
Indication Expansion	Expanding	Strategy to grow revenue by broadening indications for existing drugs
Pipeline	New Growth	Follow-on new-drug pipeline targeting CNS conditions such as migraine

Axsome Therapeutics generates revenue from the direct sale of its marketed depression and sleep-disorder treatments, and sales of these drugs are growing rapidly. The company is diversifying its growth drivers by expanding indications for existing drugs and developing follow-on new drugs for migraine and other conditions. CNS disorders represent an area of high unmet need with significant growth potential, but profitability remains volatile due to commercialization-stage selling and marketing costs and R&D investment. Revenue growth of marketed drugs and clinical pipeline results determine the company's value.

📐 Axsome Therapeutics Market Cap and Company Scale

Market capitalization stands at $12.1B, and the number of 925명 has not been publicly disclosed.

As a biopharmaceutical company that has entered the commercialization stage in the CNS treatment field, it directly markets and sells depression and sleep-disorder therapies. It is currently expanding its growth drivers through indication expansion and a follow-on new-drug pipeline in the high-unmet-need CNS space.

📈 Axsome Therapeutics Outlook and Stock Performance

📊 최근 1년 주가흐름

🎯 애널리스트 컨센서스

1.2

매도 보유 적극 매수

목표가 $281 +19.9% 현재 $235

📏 52주 가격 범위

$235

최저 $96 최고 $260

최저 대비 +144.19% 최고 대비 -9.82%

Revenue growth of marketed drugs, indication expansion, and clinical/regulatory progress of the follow-on new-drug pipeline are the medium- to long-term drivers. CNS conditions such as depression and migraine have high unmet need and significant growth potential, and indication expansion and new drug launches can lift revenue. However, uncertainty around clinical and regulatory outcomes for new drugs, commercialization-stage cost burdens and profitability volatility, as well as competing drugs and drug-pricing policy changes, can act as short- to medium-term earnings variables.

• Revenue growth of marketed drugs and indication expansion
• Clinical progress of the CNS follow-on new-drug pipeline
• Large CNS market with high unmet need

⚔️ Axsome Therapeutics Core Strengths and Risks

Marketed CNS drugs, indication expansion, and a robust pipeline are strengths, while new-drug development uncertainty, commercialization costs, and competition/pricing are the core risks.

💪 Core Strengths

Marketed Drugs

The company directly markets and sells depression and sleep-disorder treatments and has reached the commercialization stage.

Indication Expansion

It is broadening indications for existing drugs to increase revenue growth potential.

Growth Potential

Significant growth potential through the pipeline in the high-unmet-need CNS market.

⚠️ Core Risks

Development Uncertainty

Uncertainty in new-drug clinical and regulatory outcomes means pipeline results may fall short of expectations.

Commercialization Costs

Profitability remains volatile due to commercialization-stage selling and marketing costs and R&D investment.

Competition & Pricing

Entry of competing drugs and changes in drug-pricing policy could affect profitability.

Here is the rewritten sentence:

Axsome Therapeutics Competitors and Related Stocks

Axsome Therapeutics is compared alongside other biopharmaceutical companies operating in the CNS new-drug space. In CNS treatments, NBIX and sleep/neurology-focused JAZZ are frequently cited peers within the same business area.

⚔️ 경쟁주

종목	회사명	가격	등락	시총	PER	PBR	ROE	배당률
NBIX	Neurocrine Biosciences Inc	$185.50	+2.6%	$18.7B	28.5	5.5	22.5%	-
JAZZ	Jazz Pharmaceuticals plc	$258.38	+0.9%	$16.2B	-	3.6	0.68%	-

✅ Axsome Therapeutics Investor Checkpoints

Axsome Therapeutics is a U.S. biopharmaceutical company that develops and sells CNS therapies for depression and sleep disorders. Its marketed drugs and robust pipeline are appealing, but investors should also weigh new-drug development uncertainty and commercialization costs.

Uncertainty in new-drug clinical and regulatory outcomes, commercialization-stage cost burdens, entry of competing drugs, and drug-pricing policy changes can all affect earnings, so revenue growth of marketed drugs should be reviewed alongside pipeline clinical results.

Axsome Therapeutics is a U.S. biopharmaceutical company with marketed CNS drugs, an active indication-expansion strategy, and a robust pipeline. However, given new-drug development uncertainty, commercialization costs, and competition/pricing variables, it is advisable to understand the volatility and approach the stock from a medium- to long-term perspective.